18 research outputs found
Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Figure 5. CDR and clinical benefit rate within the longitudinal predictive ctDNA analysis.</p
Supplementary Table S13 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Table 13. Alternative methodologies used for the calculation of CDR and PFS predictions.</p
Supplementary Table S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Table 4. Baseline characteristics comparison between our selected study population and the overall PEARL population.</p
Supplementary Table S6 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Table 6. Summary of all baseline mutations identified for the 146 patients with ctDNA detection.</p
Supplementary Table S9 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Table 9. Summary of PFS results for ESR1 and PIK3CA mutations. Cox regression univariate and multivariate analysis.</p
Supplementary Table S12 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Table 12. Baseline genomic landscape of mutations distribution for the CDR population (n=120), by number of mutations or presence/absence, across treatment arms.</p
Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Figure 1. Survival analysis in baseline population (C1D1).</p
Supplementary Table S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Table 1. List of the 21 genes included in the breast cancer panel used for sequencing, and the targeted coding regions in each case.</p
Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Figure 4. OS analysis in baseline population (C1D1) on ESR1 and PIK3CA mutations, within the population with any detectable mutation (N=146).</p
Supplementary Table S7 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Table 7. Baseline genomic landscape of mutations distribution in population, by number of mutations or presence/absence, across treatment arms.</p